CT 2576
Latest Information Update: 06 Jun 2001
Price :
$50 *
At a glance
- Originator Cell Therapeutics
- Class Antivirals
- Mechanism of Action Immunosuppressants; Interleukin 2 inhibitors; T lymphocyte inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cytomegalovirus infections; HIV infections; Nephritis; Rheumatoid arthritis; Systemic lupus erythematosus; Transplant rejection
Most Recent Events
- 06 Jun 2001 Discontinued-Preclinical for Cytomegalovirus infections in USA (Unknown route)
- 06 Jun 2001 Discontinued-Preclinical for HIV infections treatment in USA (Unknown route)
- 06 Jun 2001 Discontinued-Preclinical for Nephritis in USA (Unknown route)